Skip to Content

UK Edition. Click here for US version.



PDF options:  View Fullscreen   Download PDF

PDF Transcript

Package Leaflet: Information for the User

Ranitidine 25 mg/ml Solution for Injection or Infusion
(Ranitidine Hydrochloride)
The name of your medicine is Raniditine 25 mg/ml solution for Injection or infusion, which will be called Ranitidine
Injection throughout this leaflet.
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their
symptoms are the same as yours.
- If any of the side effect gets serious, or if you notice any side effects not listed in this leaflet, please tell
your doctor or pharmacist.
In this leaflet:
1.What Ranitidine Injection is and what it is used for
2.Before you are given Ranitidine Injection
3.How you are given Ranitidine Injection
4.Possible side effects
5.How to store Ranitidine Injection
6.Further information
Ranitidine Injection belongs to a group of medicines called H2 receptor antagonists. Ranitidine lowers the amount
of acid in your stomach. Your doctor has prescribed Ranitidine Injection for:
• treatment of stomach ulcers and ulcers in the duodenum (where the stomach empties into),
• treatment of reflux oesophagitis (acid in the food pipe) often called heartburn
• treatment of Zollinger-Ellison-Syndrome (a condition where too much acid is produced in the stomach)
• prevention of bleeding in the gut in seriously ill patients
• prevention of bleeding in the gut in patients with bleeding stomach ulcers
• prevention of acid coming up from the stomach while under anaesthesia during an operation
You should not be given Ranitidine Injection, if you:
- are allergic (hypersensitive) to Ranitidine or any of the other ingredients of Ranitidine Injection (see list
of ingredients in Section 6). An allergic reaction may include rash, itching, difficulty of breathing or swelling of
the face, lips, throat or tongue
- have a rare condition called acute porphyria (an enzyme deficiency affecting the blood)
Take special care with Ranitidine Injection and tell your doctor if any of the following apply to you:

kidney disorder
stomach Carcinoma (tumour)
bradycardia (Slowness of the heart rate)
your immune system is not working properly
you are elderly

Taking other medicines
Please tell your doctor or pharmacist, if you are taking, or have recently taken any other medicines, including
medicines obtained without a prescription. It is especially important to tell your doctor if you are taking the following
medicines, as they may react with Ranitidine Injection:
• diazepam, for worry or anxiety problems
• lidocaine, a local anaesthetic
• phenytoin, for epilepsy
• propranolol, procainamide or n-acetylprocainamide, for heart problems
• theophylline, for breathing problems (asthma)
• warfarin, for thinning your blood
• glipizide, for lowering blood glucose
• atazanavir or delaviridine, for treating HIV infection
• triazolam, for insomnia
• gefitnib & erlotinib, for treating certain cancers
• ketoconazole, an anti fungal medicine, sometimes used for treating thrush
• itraconazole & posaconazole, for fungal infections
• midazolam, a sedative sometimes used before an operation
• Procainamide or N-acetylprocainamide, used to treat an irregular heart rhythm
• Cyanocobalamin, for anaemia
It may still be all right for you to be given Ranitidine Injection. Your doctor will be able to decide what is suitable for
Fertility, Pregnancy and breast-feeding
Ask your doctor or pharmacist for advice before taking any medicine.
You should not be given Ranitidine Injection while pregnant unless your doctor tells you to.
Clinical experience with a large number of pregnancies does not indicate adverse effects on pregnancy or the
health of the unborn child/newborn.
The active substance passes into breast milk. You should avoid breast-feeding while you are being given
Ranitidine Injection as this may cause stomach acid secretion disorders in your child.
Ranitidine had no effect on male or female fertility in animals.
Driving and using machines
Ranitidine Injection may cause hallucinations (seeing or hearing things), dizziness, confusion or headache. If you
are affected you should not drive or use machinery.
Important information about some of the ingredients of Ranitidine Injection
Ranitidine Injection contains less than 1 mmol sodium (0.08475 mmol per mL) per dose and is essentially ‘sodiumfree’ and less than 1 mmol (0.718 mmol) potassium per 100ml, i.e. essentially “potassium free”.


Ranitidine Injection will be given to you by your doctor or pharmacist.
Adults (including elderly): Ranitidine Injection will be given to you either:
• as a slow infusion into a vein (where the drug is slowly given to you over a few minutes).
• as a continuous infusion into a vein (where the drug is slowly given to you over a few hours)

Different doses may also be given to you as a slow infusion or continuous infusion, depending on what condition
you are being treated for.
Patients with a kidney disorder may need a lower dose. Your doctor will take responsibility for calculating the
appropriate dose and frequency of injections.
Children: Ranitidine Injection may be given as a slow (over 2 minutes) i.v. Injection up to a maximum of 50 mg
every 6 to 8 hours.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
If you are given more Ranitidine Injection than you should:
It is unlikely you will be given too much Ranitidine Injection, however no problems would be expected.
Like all medicines, Ranitidine Injection can cause side effects, although not everybody gets them.
Tell your doctor straight away if you get any sudden wheeziness, difficulty in breathing, swelling of the
eyelids, face or lips, rash or itching (especially affecting your whole body).
Side effects can be listed according to how often they occur:
very common: affects more than 1 user in 10
common: affects 1 to 10 users in 100
uncommon: affects 1 to 100 users in 1,000
rare: affects 1 to 1000 users in 10,000
very rare: affects less than 1 user in 10,000
unknown: cannot be estimated from the available data.
Common: Headache (sometimes severe), dizziness, diarrhoea.
Uncommon: nettle rash, serious allergic reaction that causes swelling of the face or throat, fever, asthma-like
symptoms, low blood pressure, chest pain, blurred vision, skin rash, hallucinations (seeing or hearing things),
mental confusion (these symptoms disappear when treatment is stopped).
Very rare: depression, movement disorders (including tremors or eye movements), changes in liver function tests
Unknown: changes in the number of blood cells or platelets (these can be detected by a test carried out by a
doctor), Anaphylactic shock, laryngeal spasm, confusion and hallucinations, agitation, slow or irregular heartbeat,
inflammation of the veins, pancreas or liver, nausea, yellow eyes and skin, red spots, hair loss, joint or muscle pain,
kidney damage (this can be detected by a test carried out by a doctor), failure to get an erection, breast
development in men, severe itching, increased plasma creatinine, weakness, feeling sick, and constipation
If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please tell
your doctor or pharmacist.
The hospital pharmacist will know how to store Ranitidine Injection. It should be kept out of the reach and sight of
children and do not stored above 25ºC. It should be stored in the original carton to protect from light and not
refrigerated or frozen.
Ranitidine Injection should not be autoclaved.
Do not use Ranitidine Injection after the expiry date which is stated on the label or carton after Exp. The expiry date
refers to the last day of the month.
Medicines should not be disposed of in waste-water or with household garbage. Ask your pharmacist what you
should do with medications you no longer need. These measures will help to protect the environment.
Single dose container.
Shelf life after first opening of the container: From a microbiological point of view, the product should be used
Shelf life after dilution: This medicinal product must not be mixed with other medicinal products except those
mentioned in the following:
0.9% Sodium Chloride BP
5% Dextrose BP
0.18% Sodium Chloride and 4% Dextrose BP
4.2% Sodium Bicarbonate BP
Hartmann's Solution.
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use
storage times and conditions prior to use are the responsibility of the user and would normally not be longer than
24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated conditions.
What Ranitidine Injection contains
1ml of Solution for Injection contains 25 mg Ranitidine.
Each 2 ml ampoule contains 50 mg Ranitidine (as Ranitidine Hydrochloride).
The other ingredients are:
Sodium Chloride (for tonicity adjustment),
Potassium Dihydrogen Phosphate,
Anhydrous Disodium Hydrogen Phosphate and
Water for Injections.
What Ranitidine Injection looks like and contents of the pack
Ranitidine Injection comes as a 2 ml solution in a clear glass ampoule, which are blister packed in cartons of 5, 10
and 25 ampoules.
Ranitidine Injection looks as a clear, colourless to pale yellow solution, free from visible particles.
Marketing Authorisation Holder
Claris Lifesciences (UK) Limited
Crewe Hall, Crewe, Cheshire, CW1 6UL, United Kingdom.
Peckforton Pharmaceuticals Limited
Crewe Hall, Crewe, Cheshire, CW1 6UL, United Kingdom.
This medicinal product is authorised in the Member States of the EEA under the following names:
United Kingdom

Ranitidine Claris 25mg/ml Solution for Injection or Infusion
Ranitidine Claris 25mg/ml Injektionslösung
Ranitidine Claris
Ranitidine Claris
Ranitidine Claris 25mg/ml Solution for Injection or Infusion
Ranitidină Claris 25mg/ml soluţie injectabilă/perfuzabilă
Ranitidine Claris

This leaflet was last revised in Nov’2010

+ Expand Transcript

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.